The Applications of PD1 Monoclonal Antibody in Non-small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

The study finds that PD-1 monoclonal antibodies improve survival in NSCLC patients, highlighting issues like drug resistance and adverse reactions.

PD-1 monoclonal antibodies can significantly improve survival rates in non-small cell lung cancer.
Combination treatments with PD-1 mAbs have shown increased objective response rates and patient survival.
The study elaborates on various PD-1 mAb therapies, including pembrolizumab, atelizumab, and nivolumab.
Effective management strategies for immune-related adverse events and drug resistance are crucial for successful therapy.

Zhao Su (2025) studied this question.

View Full Paper

Ask AI

Bookmark

The study finds that PD-1 monoclonal antibodies improve survival in NSCLC patients, highlighting issues like drug resistance and adverse reactions.